Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Blood

Volumn 113, Issue 21, 2009, Pages 5074-5082

  Martin, Paul J ^a,b   Storer, Barry E ^a,c   Rowley, Scott D ^d   Flowers, Mary E D ^a,b   Lee, Stephanie J ^a,b   Carpenter, Paul A ^a,b   Wingard, John R ^e   Shaughnessy, Paul J ^f   DeVetten, Marcel P ^g   Jagasia, Madan ^h   Fay, Joseph W ⁱ   Van Besien, Koen ^j   Gupta, Vikas ^k   Kitko, Carrie ^l   Johnston, Laura J ^m   Maziarz, Richard T ⁿ   Arora, Mukta ^o   Jacobson, Pamala A ^o   Weisdorf, Daniel ^o  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f TEXAS TRANSPLANT INSTITUTE   (United States)

^g UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF MICHIGAN   (United States)

^m STANFORD UNIVERSITY   (United States)

ⁿ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^o UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; AVASCULAR NECROSIS; BACTERIAL INFECTION; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE CRAMP; MYCOSIS; NEUTROPENIA; NONHUMAN; ORGAN TRANSPLANTATION; OSTEOPOROSIS; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; THROMBOCYTOPENIA; THYROID DISEASE; TINNITUS; URTICARIA; VIRUS INFECTION; CHRONIC DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KARNOFSKY PERFORMANCE STATUS; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE; TREATMENT OUTCOME;

CAUSE OF DEATH; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67149108714     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-202937     Document Type: Article

References (42)

1. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215-233.
2. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72:555-561. (Pubitemid 18226261)
3. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104:3501-3506. (Pubitemid 39564419)
4. Axelrod L. Glucocorticoid therapy. Medicine. 1976;55:39-65.
5. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
6. Nash RA, Furlong T, Storb R, et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host-disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT): safety analysis. Blood. 1997;90:105a.
7. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-520. (Pubitemid 29423631)
8. Yusuf U, Sanders JE, Stephan V. Mycophenolate mofetil (MMF) as salvage treatment for steroid-refractory chronic graft versus-host disease (GVHD) in children. Blood. 2001;98:398a. (Pubitemid 33787768)
9. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc. 2001;33:2121-2123. (Pubitemid 33762653)
10. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287-295.
11. Busca A, Locatelli F, Marmont F, Audisio E, Falda M. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease. Haematologica. 2003;88:837-839. (Pubitemid 36890123)
12. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004;73:56-61.
13. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005;84:681-685. (Pubitemid 41554245)
14. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307-313. (Pubitemid 40450758)
15. Takami A, Mochizuki K, Okumura H, et al. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory and chronic graft-versus-host disease. Int J Hematol. 2006;83:80-85. (Pubitemid 43172748)
16. Lee SJ, Volgelsang G, Gilman A, et al. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8:32-39. (Pubitemid 34141549)
17. Pavletic S, Vogelsang GB. Treatment of high-risk chronic GVHD. Biol Blood Marrow Transplant. 2008;14:1436-1437.
18. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transplant Immunol. 1997;5:225-232. (Pubitemid 27489255)
19. Smak Gregoor PJH, de Sevaux RGL, Hene RJ, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999;68:1603-1606.
20. Mourad M, Malaise J, Chaib ED, et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem. 2001;47:1241-1248. (Pubitemid 32579112)
21. Mourad M, Malaise J, Chaib ED, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001;47:88-94. (Pubitemid 32064280)
22. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies [review]. Am J Transplant. 2003;3:534-542. (Pubitemid 36612836)
23. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit. 2001;23:35-38. (Pubitemid 32105962)
24. Flechner SM, Feng J, Mastroianni B, et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation. 2005;79:926-934. (Pubitemid 40586865)
25. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196-1201. (Pubitemid 32183739)
26. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant. 2006;12:375-396.
27. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
28. Weber LT, Lamersdorf T, Shipkova M, et al. Area under the plasma concentration time-curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant recipients. Ther Drug Monit. 1999;21:498-506.
29. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266. (Pubitemid 29360288)
30. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005;78:486-500. (Pubitemid 41698903)
31. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706. (Pubitemid 29126745)
32. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2007;110:2744-2748. (Pubitemid 47523200)
33. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945-956.
34. Pavletic S, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006;12:252-266.
35. Ng J, Rogosheske J, Barker J, Weisdorf D, Jacobson PA. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit. 2006;28:394-401. (Pubitemid 44314928)
36. Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675-1685.
37. Jeong J, Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol. 2007;2:184-191.
38. Jacobson P, Green KG, Hering BJ. Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol. 2005;45:901-909. (Pubitemid 41060229)
39. Jacobson P, El-Massah SF, Rogosheske J, et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant. Prepublished on January 19, 2009, as DOI 10.1038/bmt.2008.428.
40. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-554. (Pubitemid 18226260)
41. Chaingne-Delalande B, Guidicelli G, Couzi L, et al. The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal. J Immunol. 2008;181:7630-7638.
42. Chu YW, Gress R. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14:365-378.